Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CLIC1 | O00299 | 1/20 | 0.37 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27773589 | 0.90 | PTGS2 (0.53) | PTGS2ABCB11PTGS1PPARGNR1I3 | |
| SCHEMBL3870142 | 0.89 | PTGS2 (0.52) | PTGS2ABCB11PTGS1PPARGNR1I3 | |
| SCHEMBL3869939 | 0.88 | PTGS2 (0.51) | PTGS2ABCB11PTGS1PPARGNR1I3 | |
| SCHEMBL3870953 | 0.87 | PTGS2 (0.40) | PTGS2ABCB11PTGS1PPARGNR1I3 | |
| SCHEMBL4321256 | 0.87 | PTGS2 (0.40) | PTGS2ABCB11PTGS1PPARGNR1I3 | |
| SCHEMBL3874288 | 0.85 | PTGS2 (0.48) | PTGS2ABCB11PTGS1PPARGNR1I3 | |
| SCHEMBL3871928 | 0.79 | PTGS2 (0.65) | PTGS2ABCB11PTGS1PPARGNR1I3 | |
| SCHEMBL3873191 | 0.78 | PTGS2 (0.40) | PTGS2ABCB11PTGS1PPARGNR1I3 | |
| SCHEMBL27773596 | 0.78 | PTGS2 (0.40) | PTGS2ABCB11PTGS1PPARGNR1I3 | |
| SCHEMBL3881581 | 0.77 | PTGS2 (0.47) | PTGS2ABCB11PTGS1PPARGNR1I3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209648-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | claimed |
| CN-101479231-A | Phenylacetic acid derivatives as COX-2 inhibitors | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | claimed |
| US-20140058129-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8586782-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-11-19 | — | — | US | disclosed |
| US-8362294-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | MONOVICH LAUREN G (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2046723-B1 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | NOVARTIS AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| CN-101479231-A | Phenylacetic acid derivatives as COX-2 inhibitors | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| EP-2046723-A2 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | Novartis AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| EP-2014284-A1 | Pharmaceutical compositions and uses | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008156645-A2 | PHARMACEUTICAL COMPOSITIONS AND USES | NOVARTIS AG (CH) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008002853-A2 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058129-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | PTGS2 2/4885ABCB11 211/4885PTGS1 8/4885 |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | PTGS2 2/4885ABCB11 211/4885PTGS1 8/4885 |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, PTGER2 | PTGS2 2/4885ABCB11 217/4885PTGS1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.